Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Epidemiol Infect ; 140(1): 115-25, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21303590

RESUMO

There is concern that widespread usage of ertapenem may promote cross-resistance to other carbapenems. To analyse the impact that adding ertapenem to our hospital formulary had on usage of other broad-spectrum agents and on susceptibilities of nosocomial Enterobacteriaceae and Pseudomonas isolates, we performed interrupted time-series analyses to determine the change in linear trend in antibiotic usage and change in mean proportion and linear trend of susceptibility pre- (March 2004-June 2005) and post- (July 2005-December 2008) ertapenem introduction. Usage of piperacillin-tazobactam (P=0·0013) and ampicillin-sulbactam (P=0·035) declined post-ertapenem introduction. For Enterobacteriaceae, the mean proportion susceptible to ciprofloxacin (P=0·016) and piperacillin-tazobactam (P=0·038) increased, while the linear trend in susceptibility significantly increased for cefepime (P=0·012) but declined for ceftriaxone (P=0·0032). For Pseudomonas, the mean proportion susceptible to cefepime (P=0·011) and piperacillin-tazobactam (P=0·028) increased, as did the linear trend in susceptibility to ciprofloxacin (P=0·028). Notably, no significant changes in carbapenem susceptibility were observed.


Assuntos
Antibacterianos/administração & dosagem , Infecção Hospitalar/microbiologia , Prescrições de Medicamentos/estatística & dados numéricos , Enterobacteriaceae/efeitos dos fármacos , Pseudomonas/efeitos dos fármacos , beta-Lactamas/administração & dosagem , Antibacterianos/farmacologia , Farmacorresistência Bacteriana/efeitos dos fármacos , Enterobacteriaceae/isolamento & purificação , Ertapenem , Humanos , Pseudomonas/isolamento & purificação , Análise de Regressão , beta-Lactamas/farmacologia
2.
Bone Marrow Transplant ; 27(5): 537-42, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11313689

RESUMO

Viridans streptococci were the most common cause of bacteremia in 61 consecutive myeloablative allogeneic hematopoietic stem cell transplant (HSCT) recipients, occurring in 19 of 31 bacteremic patients (61%) during the period of post-transplant neutropenia. Seven of the 19 had more than one viridans streptococcus in the same blood culture. Twenty isolates from 15 patients were Streptococcus mitis. Most viridans streptococci were resistant to norfloxacin, used routinely for prophylaxis. Comparison of the 19 patients with viridans streptococcal bacteremia with a contemporaneous group of 23 allogeneic HSCT recipients with fever and neutropenia but no identified focus of infection found that patients with viridans streptococcal bacteremia were more likely to have severe intraoral pathology while neutropenic (26% vs 0%) and slightly shorter interval between the last dental procedure and the onset of neutropenia (11 vs 14 days). Poor underlying dental health and the use of norfloxacin thus appear to predispose to viridans streptococcal bacteremia.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Doenças Estomatognáticas/complicações , Infecções Estreptocócicas/etiologia , Adulto , Antibacterianos/administração & dosagem , Bacteriemia/tratamento farmacológico , Bacteriemia/etiologia , Feminino , Neoplasias Hematológicas/complicações , Neoplasias Hematológicas/terapia , Humanos , Masculino , Testes de Sensibilidade Microbiana , Infecções Estreptocócicas/tratamento farmacológico , Transplante Homólogo/efeitos adversos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...